Q-omics provides the consensus-scored CDCA7L profile across patient tissues and cancer cell-line models. CDCA7L expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CDCA7L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CDCA7L RNA expression shows 19,725 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where CDCA7L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDCA7L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDCA7L survival associations across molecular data types. CDCA7L RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDCA7L RNA expression–survival associations across cancer types. High CDCA7L expression shows unfavorable associations in KICH, ACC, LIHC, BLCA and LGG, but favorable associations in UVM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CDCA7L RNA expression.
This table summarizes CDCA7L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CDCA7L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDCA7L shows higher tumor expression in KIRC, COAD, HNSC, KIRP, CHOL and LUSC. The KIRC box plot shows higher CDCA7L RNA expression in tumor versus normal tissue (log2 FC = +1.797, t-test p < 0.001).
This table shows molecular features associated with CDCA7L in patient tissues and cancer cell lines. In patient samples, CDCA7L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDCA7L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
